IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v14y2013i6p875-885.html
   My bibliography  Save this article

Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

Author

Listed:
  • P. Laires
  • F. Exposto
  • R. Mesquita
  • A. Martins
  • L. Cunha-Miranda
  • J. Fonseca

Abstract

Variations in RA PAB were found across selected countries with Portugal showing the lowest proportion. GDP per capita, biologics distribution channel and consumption of MTX appear to be the best explanatory factors for these fluctuations in European countries. Copyright Springer-Verlag 2013

Suggested Citation

  • P. Laires & F. Exposto & R. Mesquita & A. Martins & L. Cunha-Miranda & J. Fonseca, 2013. "Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 875-885, December.
    • Handle: RePEc:spr:eujhec:v:14:y:2013:i:6:p:875-885
    DOI: 10.1007/s10198-012-0432-5
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-012-0432-5
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-012-0432-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. J. Smolen & D. Aletaha, 2008. "The burden of rheumatoid arthritis and access to treatment: a medical overview," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 39-47, January.
    2. B. Jönsson & G. Kobelt & J. Smolen, 2008. "The burden of rheumatoid arthritis and access to treatment: uptake of new therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 61-86, January.
    3. J. Lundkvist & F. Kastäng & G. Kobelt, 2008. "The burden of rheumatoid arthritis and access to treatment: health burden and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 49-60, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Valentin Brodszky & Petra Baji & Orsolya Balogh & Márta Péntek, 2014. "Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 65-71, May.
    2. László Gulácsi, 2014. "Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 1-4, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.
    2. Kurt Brekke & Dag Dalen & Tor Holmås, 2014. "Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
    3. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.
    4. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    5. Benjamin Birkner & Jürgen Rech & Tom Stargardt, 2020. "Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-17, January.
    6. Sonja Merkesdal & Timm Kirchhoff & Diane Wolka & Gunter Ladinek & Adrian Kielhorn & Andrea Rubbert-Roth, 2010. "Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 95-104, February.
    7. Bogdan Batko & Paulina Rolska-Wójcik & Magdalena Władysiuk, 2019. "Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review," IJERPH, MDPI, vol. 16(16), pages 1-16, August.
    8. Ulf Persson, 2012. "Value Based Pricing in Sweden: Lessons for Design?," Seminar Briefing 000141, Office of Health Economics.
    9. Azucena Pedraz-Marcos & Ana María Palmar-Santos & Claire Anne Hale & Juan Zarco-Colón & Milagros Ramasco-Gutiérrez & Eva García-Perea & Teresa Velasco-Ripoll & Josefina Martín-Alarcón & Nuria Sa, 2020. "Living With Rheumatoid Arthritis in Spain: A Qualitative Study of Patient Experience and the Role of Health Professionals," Clinical Nursing Research, , vol. 29(8), pages 551-560, November.
    10. Karine Chevreul & Georges Haour & Sandy Lucier & Stephanie Harvard & Marie-Laure Laroche & Xavier Mariette & Alain Saraux & Isabelle Durand-Zaleski & Francis Guillemin & Bruno Fautrel, 2014. "Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort," PLOS ONE, Public Library of Science, vol. 9(5), pages 1-9, May.
    11. Márta Péntek & László Gulácsi & Bernadette Rojkovich & Valentin Brodszky & Job Exel & Werner Brouwer, 2014. "Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 83-92, May.
    12. Jaana T Joensuu & Saara Huoponen & Kalle J Aaltonen & Yrjö T Konttinen & Dan Nordström & Marja Blom, 2015. "The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-27, March.
    13. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2012. "The State of Health Economic Research in South Africa," PharmacoEconomics, Springer, vol. 30(10), pages 925-940, October.
    14. László Gulácsi, 2010. "Future challenges for health economics and health technology assessment of biological drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 235-238, June.

    More about this item

    Keywords

    Rheumatoid arthritis; Treatment access; Biologics; Portugal; I11;
    All these keywords.

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:14:y:2013:i:6:p:875-885. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.